Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Debiopharm Group

Latest From Debiopharm Group

Deal roundup: Zymeworks/Celgene, Curis/Aurigene, MedImmune/NCI

Zymeworks will earn up to $164m in clinical, regulatory and commercial milestone fees plus royalties for each bi-specific antibody developed under a new collaboration with Celgene.

Gastrointestinal Cancer

Deal Watch: Roche/Foundation Medicine Highlights Hyper Deal-Making During J.P. Morgan

Biogen will purchase GSK spinout Convergence to bolster its pain portfolio, while Tekmira and OnCore are merging to create a new company focused on hepatitis B. Two J&J units struck deals during the week in Alzheimer’s and gastrointestinal indications, as Lilly teamed up with Merck and Bristol for combo trials to keep its drugs relevant in the PD-1 world.

BioPharmaceutical Deals

Novartis returns Debiopharm's alisporivir after Hep C exit

Novartis has returned all rights of Debiopharm's hepatitis C virus (HCV) compound alisporivir in line with the company's decision to pull out of HCV.


Novartis quits hepatitis C

Novartis has decided to throw in the towel over hepatitis C. "As part of an ongoing portfolio transformation, hepatitis C virus (HCV) will no longer be a strategic focus," the pharma major has confirmed. As a result, Novartis has terminated its licensing agreement with Enanta Pharmaceuticals for the development of EDP239, an NS5A inhibitor currently in Phase I development for the treatment of HCV. However, "Ongoing trials in HCV will not be affected by this decision and these trials will be completed as planned," it added.

See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Debio Group
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Debiopharm Group
  • Senior Management
  • Rolland-Yves Mauvernay, Co-Pres.
    Thierry Mauvernay, Co-Pres.
  • Contact Info
  • Debiopharm Group
    Phone: (41) 21 321 0111
    Chemin Messidor 5-7
    P.O. Box 5911 Lausanne, CH-1002